VRTX VERTEX PHARMACEUTICALS INC / MA
Pharmaceutical Preparations · Nasdaq · SEC CIK 875320 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.5%
TTM net income YoY8.2%
TTM EPS YoY9.4%
Revenue 3-yr CAGR10.3%
Net income 3-yr CAGR4.6%
Margins
Gross margin85.5%
Operating margin33.2%
Net margin30.7%
FCF margin24.7%
EBITDA margin35.1%
Returns
ROE20.8%
ROA13.8%
ROIC (approx.)21.9%
Asset turnover0.45x
Leverage & solvency
Liabilities / assets36.1%
Debt / equity0.22x
Current ratio2.34x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio1.0%
Payout ratio—
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $12.00B | $11.02B |
| Cost of revenue | $1.65B | $1.53B |
| Gross profit | $10.35B | $9.49B |
| R&D expense | $3.91B | $3.63B |
| SG&A expense | $1.75B | $1.46B |
| Operating income | $4.17B | -$232.90M |
| Interest expense | $13.30M | $30.60M |
| Pretax income | $4.64B | $248.50M |
| Income tax | $690.00M | $784.10M |
| Net income | $3.95B | -$535.60M |
| EBITDA | $4.38B | -$25.70M |
| EPS (basic) | 15.46 | -2.08 |
| EPS (diluted) | 15.32 | -2.08 |
| Weighted avg. shares (diluted) | 258.00M | 257.90M |
| Balance sheet | ||
| Cash & equivalents | $5.08B | $4.57B |
| Short-term investments | $1.52B | $1.55B |
| Receivables | $2.05B | $1.61B |
| Inventory | $1.69B | $1.21B |
| Current assets | $11.20B | $9.60B |
| PP&E, net | $1.52B | $1.23B |
| Goodwill | $1.09B | $1.09B |
| Intangibles | $424.20M | $825.90M |
| Total assets | $25.64B | $22.53B |
| Current liabilities | $3.86B | $3.56B |
| Short-term debt | $0 | — |
| Long-term debt | $0 | — |
| Total debt | $0 | — |
| Total liabilities | $6.98B | $6.12B |
| Shareholders' equity | $18.67B | $16.41B |
| Net debt | -$5.08B | — |
| Shares outstanding | 253.99M | 256.94M |
| Cash flow statement | ||
| Operating cash flow | $3.63B | -$492.60M |
| Capital expenditure | $437.60M | $297.70M |
| Free cash flow | $3.19B | -$790.30M |
| Investing cash flow | -$945.40M | -$3.77B |
| Financing cash flow | -$2.26B | -$1.49B |
| Depreciation & amortization | $209.80M | $207.20M |
| Stock-based compensation | $685.90M | $698.50M |
| Share buybacks | $2.02B | $1.18B |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.